Logo image of CPRX

CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

NASDAQ:CPRX - Nasdaq - US14888U1016 - Common Stock

22.92  +0.14 (+0.61%)

After market: 23.1975 +0.28 (+1.21%)

Fundamental Rating

8

Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 572 industry peers in the Biotechnology industry. CPRX gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings would make CPRX suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

CPRX had positive earnings in the past year.
CPRX had a positive operating cash flow in the past year.
Each year in the past 5 years CPRX has been profitable.
CPRX had a positive operating cash flow in each of the past 5 years.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

1.2 Ratios

CPRX's Return On Assets of 18.50% is amongst the best of the industry. CPRX outperforms 98.41% of its industry peers.
The Return On Equity of CPRX (21.61%) is better than 97.35% of its industry peers.
CPRX has a Return On Invested Capital of 20.22%. This is amongst the best in the industry. CPRX outperforms 98.23% of its industry peers.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.38%. This is significantly above the industry average of 13.83%.
Industry RankSector Rank
ROA 18.5%
ROE 21.61%
ROIC 20.22%
ROA(3y)17.98%
ROA(5y)24.26%
ROE(3y)21.72%
ROE(5y)29.16%
ROIC(3y)20.38%
ROIC(5y)21.58%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

1.3 Margins

CPRX has a Profit Margin of 31.01%. This is amongst the best in the industry. CPRX outperforms 98.23% of its industry peers.
In the last couple of years the Profit Margin of CPRX has declined.
CPRX's Operating Margin of 37.78% is amongst the best of the industry. CPRX outperforms 99.11% of its industry peers.
CPRX's Operating Margin has declined in the last couple of years.
CPRX has a better Gross Margin (86.32%) than 89.73% of its industry peers.
CPRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 37.78%
PM (TTM) 31.01%
GM 86.32%
OM growth 3Y-14.33%
OM growth 5YN/A
PM growth 3Y-34.21%
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5YN/A
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CPRX is creating value.
The number of shares outstanding for CPRX has been increased compared to 1 year ago.
Compared to 5 years ago, CPRX has more shares outstanding
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 17.11 indicates that CPRX is not in any danger for bankruptcy at the moment.
The Altman-Z score of CPRX (17.11) is better than 91.33% of its industry peers.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 17.11
ROIC/WACC1.82
WACC11.11%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

CPRX has a Current Ratio of 5.11. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.11, CPRX is in line with its industry, outperforming 54.69% of the companies in the same industry.
CPRX has a Quick Ratio of 4.92. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a Quick ratio of 4.92. This is comparable to the rest of the industry: CPRX outperforms 55.04% of its industry peers.
Industry RankSector Rank
Current Ratio 5.11
Quick Ratio 4.92
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

9

3. Growth

3.1 Past

CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.89%, which is quite impressive.
Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 25.48% on average per year.
The Revenue has grown by 32.13% in the past year. This is a very strong growth!
Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 280.39% on average per year.
EPS 1Y (TTM)63.89%
EPS 3Y25.48%
EPS 5YN/A
EPS Q2Q%220.69%
Revenue 1Y (TTM)32.13%
Revenue growth 3Y49.53%
Revenue growth 5Y280.39%
Sales Q2Q%25.33%

3.2 Future

Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.43% on average per year.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.81% yearly.
EPS Next Y53.42%
EPS Next 2Y41.43%
EPS Next 3Y34.8%
EPS Next 5Y32.43%
Revenue Next Year23.01%
Revenue Next 2Y20.62%
Revenue Next 3Y18.39%
Revenue Next 5Y14.81%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 19.42, which indicates a rather expensive current valuation of CPRX.
CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 95.93% of the companies in the same industry.
When comparing the Price/Earnings ratio of CPRX to the average of the S&P500 Index (28.29), we can say CPRX is valued slightly cheaper.
With a Price/Forward Earnings ratio of 14.15, CPRX is valued correctly.
CPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.28% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CPRX to the average of the S&P500 Index (24.44), we can say CPRX is valued slightly cheaper.
Industry RankSector Rank
PE 19.42
Fwd PE 14.15
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.52% of the companies listed in the same industry.
CPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.88% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.21
EV/EBITDA 10.76
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
A more expensive valuation may be justified as CPRX's earnings are expected to grow with 34.80% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y41.43%
EPS Next 3Y34.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (1/21/2025, 8:00:00 PM)

After market: 23.1975 +0.28 (+1.21%)

22.92

+0.14 (+0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners83.84%
Inst Owner Change0.11%
Ins Owners5.97%
Ins Owner Change3.04%
Market Cap2.73B
Analysts87.14
Price Target32.9 (43.54%)
Short Float %5.97%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.71%
Min EPS beat(2)12.87%
Max EPS beat(2)22.55%
EPS beat(4)4
Avg EPS beat(4)15.58%
Min EPS beat(4)12.21%
Max EPS beat(4)22.55%
EPS beat(8)7
Avg EPS beat(8)11.18%
EPS beat(12)9
Avg EPS beat(12)5.88%
EPS beat(16)11
Avg EPS beat(16)4.41%
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)2.23%
Max Revenue beat(2)7.55%
Revenue beat(4)3
Avg Revenue beat(4)2.63%
Min Revenue beat(4)-1.58%
Max Revenue beat(4)7.55%
Revenue beat(8)7
Avg Revenue beat(8)2.81%
Revenue beat(12)9
Avg Revenue beat(12)2.5%
Revenue beat(16)12
Avg Revenue beat(16)2.35%
PT rev (1m)0%
PT rev (3m)6.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.77%
EPS NY rev (1m)0%
EPS NY rev (3m)10.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.19%
Valuation
Industry RankSector Rank
PE 19.42
Fwd PE 14.15
P/S 5.94
P/FCF 12.21
P/OCF 12.18
P/B 4.14
P/tB 5.52
EV/EBITDA 10.76
EPS(TTM)1.18
EY5.15%
EPS(NY)1.62
Fwd EY7.07%
FCF(TTM)1.88
FCFY8.19%
OCF(TTM)1.88
OCFY8.21%
SpS3.86
BVpS5.54
TBVpS4.15
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 18.5%
ROE 21.61%
ROCE 26.1%
ROIC 20.22%
ROICexc 60.09%
ROICexgc 231.29%
OM 37.78%
PM (TTM) 31.01%
GM 86.32%
FCFM 48.63%
ROA(3y)17.98%
ROA(5y)24.26%
ROE(3y)21.72%
ROE(5y)29.16%
ROIC(3y)20.38%
ROIC(5y)21.58%
ROICexc(3y)212.24%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.3%
ROCE(5y)27.86%
ROICexcg growth 3Y-0.3%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.77%
ROICexc growth 5YN/A
OM growth 3Y-14.33%
OM growth 5YN/A
PM growth 3Y-34.21%
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.6%
Cap/Sales 0.13%
Interest Coverage 133.21
Cash Conversion 106.18%
Profit Quality 156.82%
Current Ratio 5.11
Quick Ratio 4.92
Altman-Z 17.11
F-Score6
WACC11.11%
ROIC/WACC1.82
Cap/Depr(3y)166.9%
Cap/Depr(5y)100.14%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.15%
Profit Quality(3y)163.58%
Profit Quality(5y)131.84%
High Growth Momentum
Growth
EPS 1Y (TTM)63.89%
EPS 3Y25.48%
EPS 5YN/A
EPS Q2Q%220.69%
EPS Next Y53.42%
EPS Next 2Y41.43%
EPS Next 3Y34.8%
EPS Next 5Y32.43%
Revenue 1Y (TTM)32.13%
Revenue growth 3Y49.53%
Revenue growth 5Y280.39%
Sales Q2Q%25.33%
Revenue Next Year23.01%
Revenue Next 2Y20.62%
Revenue Next 3Y18.39%
Revenue Next 5Y14.81%
EBIT growth 1Y129.21%
EBIT growth 3Y28.1%
EBIT growth 5YN/A
EBIT Next Year158.66%
EBIT Next 3Y28.8%
EBIT Next 5YN/A
FCF growth 1Y135.22%
FCF growth 3Y47.15%
FCF growth 5YN/A
OCF growth 1Y135.85%
OCF growth 3Y47.22%
OCF growth 5YN/A